Saccharomyces boulardii CNCM I-745

Saccharomyces boulardii CNCM I-745 is among the most extensively studied probiotic yeasts, with a research base spanning randomized controlled trials, meta-analyses, and animal models. Human trials and meta-analyses have examined gut microbiota balance during and after antibiotic use, and preliminary research has examined gut-associated immune responses. Studies have also explored its role in contexts such as Helicobacter pylori co-treatment and gastrointestinal motility, though the strength and generalizability of findings vary across study designs. This strain's clinical evidence base is comparatively well-developed relative to most probiotics, though individual responses may vary and it should not be considered a treatment for any specific condition. These are research topics, not findings; the papers do not establish that this strain treats or prevents any condition.